Exploring desolvation-driven polymorph formation via multicomponent crystals of furosemide
- 3 December 2025
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 28 (2) , 534-546
Abstract
Furosemide was crystallised with five pyridine derivatives to produce multicomponent crystals that were subsequently desolvated to study their structural changes and solid-form evolution.Keywords
Funding Information
- National Research Foundation (105969)
- European Regional Development Fund (GINOP-2.3.2-15-2016-00008)
- European Regional Development Fund (GINOP-2.3.3-15-2016-00004)
- Cape Peninsula University of Technology
This publication has 39 references indexed in Scilit:
- Polymorph control by designed ultrasound application strategy: The role of molecular self-assemblyUltrasonics Sonochemistry, 2022
- Recent advances in drug polymorphs: Aspects of pharmaceutical properties and selective crystallizationInternational Journal of Pharmaceutics, 2022
- High temperature polymorphic conversion of carbamazepine in supercritical CO2: A way to obtain pure polymorph IJournal of Molecular Liquids, 2021
- First Evidence of Polymorphism in Furosemide SolvatesCrystal Growth & Design, 2017
- Solvates, Salts, and Cocrystals: A Proposal for a Feasible Classification SystemCrystal Growth & Design, 2016
- Disappearing Polymorphs RevisitedAngewandte Chemie International Edition, 2015
- X-ray structure analysis and vibrational spectra of FurosemideVibrational Spectroscopy, 2012
- Thermal behavior of furosemideJournal of Thermal Analysis and Calorimetry, 2011
- Effect of the damping function in dispersion corrected density functional theoryJournal of Computational Chemistry, 2011
- Physicochemical characterization of furosemide modificationsInternational Journal of Pharmaceutics, 1990